Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 9, 2024Neurology

Real-world Data on Ocrelizumab Treatment: Efficacy, Safety, and Tolerability Analysis in Patients with Relapsing Remitting and Primary Progressive Multiple Sclerosis in Southeastern Ontario (P2-6.014)

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAlwaleed AljaserMBMoogeh Baharnoori

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aljaser et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677c46https://doi.org/10.1212/wnl.0000000000205391
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systematic review on Ocrevus for treatment of multiple sclerosis2024 · 1 citations
  2. 2A Retrospective, Single-Arm, Observational Study in Patients with Multiple Sclerosis in India Receiving Ocrelizumab Therapy for 1 Year2026
  3. 310 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-term Efficacy and Safety Clinical Trial Data (S31.005)2024 · 5 citations
  4. 4Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension2023 · 31 citations
  5. 5Impact of Ocrelizumab on Disease Progression, Memory Improvement, and Quality of Life in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal MRI and Clinical Criteria Analysis2024 · 4 citations